Monotherapy best percentage change from baseline in target lesion size. Data for 3 patients with DLBCL, 2 with MZL, and 1 with MCL are not shown because of nonmeasurable disease at baseline or no valid postbaseline target lesion measurements. *Best percentage change from baseline in target lesion size more than 100%.